TABLE I.
Cohort characteristics, stratified by AHR remission phenotype
| Characteristic | No remission (n = 128) | AHR remission (n = 32) | P value |
|---|---|---|---|
| Baseline age (y), mean ± SD | 8.88 ± 2.15 | 8.62 ± 2.02 | .53 |
| Sex: male, % | 49.20 | 75.00 | .0086 |
| Baseline height (cm), mean ± SD | 133.25 ± 13.85 | 130.70 ± 12.78 | .35 |
| Baseline PC20 (log mg/mL), mean ± SD | 1.48 ± 1.83 | 3.82 ± 3.29 | 2.4 × 10−7 |
| Baseline FEV1 (L), mean ± SD | 1.65 ± 0.48 | 1.62 ± 0.38 | .77 |
| Baseline FEV1 (percent predicated),mean ± SD | 93.70 ± 14.92 | 96.97 ± 13.80 | .26 |
| Baseline FEV1/FVC, mean ± SD | 78.03 ± 8.93 | 81.50 ± 7.25 | .044 |
| Baseline bronchodilator response (%), mean ± SD | 12.85 ± 11.00 | 7.28 ± 7.75 | .0077 |
| Baseline vitamin D insufficiency, count (%) | 31 (24.22) | 4 (12.50) | .15 |
| Oral steroid bursts required through trial, mean ± SD | 2.90 ± 3.53 | 2.72 ± 3.68 | .8 |
| Reduced growth longitudinal lung function pattern, n (%) | 57 (44.53) | 15 (46.88) | .81 |
| Early decline longitudinal lung function pattern, n (%) | 54 (42.19) | 14 (43.75) | .87 |
| Steroid responsiveness endophenotype, mean ± SD | 0.64 ± 1.11 | 0.48 ± 0.91 | .45 |
Reduced growth and early decline longitudinal lung function patterns as described in McGeachie et al.8 Steroid responsiveness endophenotype as described in Clemmer et al.9 P values computed using the chi-square test or the regression test.
FVC, Forced vital capacity; PC20, provocative concentration of methacholine required to effect a 20% decrease in FEV1.